2 Janin Y L. Antituberculosis drugs: Ten years of research. Bioorg Med Chem, 2007, 15: 2479-2513？？
[3]
3 Du G, Chen C Y, Shen Y, et al. TCR repertoire, clonal dominance, and pulmonary trafficking of mycobacterium-specific CD4+ and CD8+ T effector cells in immunity against tuberculosis. J Immunol, 2010, 185: 3940-3947
[4]
4 Millington K A, Gooding S, Hinks T S, et al. Mycobacterium tuberculosis-specific cellular immune profiles suggest bacillary persistence decades after spontaneous cure in untreated tuberculosis. J Infect Dis, 2010, 202: 1685-1689？？
[5]
8 He X Y, Xiao L, Chen H B, et al. T regulatory cells and Th1/Th2 cytokines in peripheral blood from tuberculosis patients. Eur J Clin Microbiol Infect Dis, 2010, 29: 643-650？？
[6]
9 Orme I M, Collins F M. Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy: Requirement for T celldeficient recipients. J Exp Med, 1983, 158: 74-83？？
[7]
10 Kitsukawa K, Higa F, Takushi Y, et al. Adoptive immunotherapy for pulmonary tuberculosis caused by multi-resistant bacteria using autologous peripheral blood leucocytes sensitized with killed Mycobacterium tuberculosis bacteria. Kekkaku, 1991, 66: 563-575
[8]
12 Thomas S, Stauss H J, Morris E C. Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology, 2010,129: 170-177？？
[9]
14 Luo W, Ma L, Wen Q, et al. Analysis of the interindividual conservation of T cell receptor alpha- and beta-chain variable regions gene in the peripheral blood of patients with systemic lupus erythematosus. Clin Exp Immunol, 2008, 154: 316-324？？
[10]
15 Kalamasz D, Long S A, Taniguchi R, et al. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti- CD3 and anti-CD28 antibodies. J Immunother, 2004, 27: 405-418？？
[11]
17 Koyama M, Izutani Y, Goda A E, et al. Histone deacetylase inhibitors and 15-deoxy-delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin Cancer Res, 2010, 16: 2320-2332
[12]
18 Geffner L, Yokobori N, Basile J, et al. Patients with multidrug-resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains. Infect Immun, 2009,77: 5025-5034？？
[13]
20 van Crevel R, Karyadi E, Preyers F, et al. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis, 2000, 181: 1194-1197？？
[14]
21 Zhang S L, Zhao J W, Sun Z Q, et al. Development and evaluation of a novel multiple-antigen ELISA for serodiagnosis of tuberculosis. Tuberculosis (Edinb), 2009, 89: 278-284？？
[15]
22 Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood, 2004, 103: 3565-3572？？
[16]
23 Jorritsma A, Gomez-Eerland R, Dokter M, et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood,2007, 110: 3564-3572？？
[17]
5 Kaufmann S H. Future vaccination strategies against tuberculosis: Thinking outside the box. Immunity, 2010, 33: 567-577？？
[18]
6 Chen X, Zhou B, Li M, et al. CD4+ CD25+ FoxP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol, 2007, 123: 50-59？？
[19]
7 Wergeland I, Assmus J, Dyrhol-Riise A M. T regulatory cells and immune activation in Mycobacterium tuberculosis infection and the effect of preventive therapy. Scand J Immunol, 2011, 73: 234-242？？
[20]
11 St Georgiev V. Treatment and developmental therapeutics of Mycobacterium tuberculosis infections. Int J Antimicrob Agents, 1994, 4:157-173？？
[21]
13 Morgan R A, Dudley M E, Wunderlich J R, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science,2006, 314: 126-129？？
[22]
16 Corrigan C J, Wang W, Meng Q, et al. T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci USA, 2011, 108: 1579-1584？？
[23]
19 Jorritsma A, Schumacher T N, Haanen J B. Immunotherapeutic strategies: The melanoma example. Immunotherapy, 2009, 1: 679-690
[24]
24 Mizuguchi H, Xu Z, Ishii-Watabe A, et al. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther, 2000, 1: 376-382？？
